Cost-Effective Innovation

November 12, 2015
Tim Mayleben
President and Chief Executive Officer

By now you’ve read the headlines about the high cost of the new cholesterol lowering drugs.  We’ve been bombarded with commentary, articles and opinion pieces on these drugs and their high prices.  The PCSK9 inhibitors – injectable, biologic drugs that dramatically lower LDL-cholesterol – appear to be very efficacious.  But these drugs are priced at… Read More

Reflections One Year Post-IPO

June 26, 2014
Tim Mayleben
President and Chief Executive Officer

One year ago today the “new” Esperion re-entered the public markets with an initial public offering that raised $80 million and with a singular focus: to rapidly advance the development of ETC-1002, a unique, first-in-class, oral, once-daily low-density lipoprotein cholesterol (LDL-C) lowering therapy for patients with hypercholesterolemia who are unable to tolerate a statin. Since… Read More

Posted In: Company News

ACC.14: Spotlighting the Importance of Finding New Therapies for Statin Intolerant Patients

April 21, 2014
Roger Newton, PhD, FAHA
Executive Chairman and Chief Scientific Officer

Late last month, the American College of Cardiology (ACC) held its 63rd Annual Scientific Session & Expo with more than 13,000 cardiovascular experts coming together in Washington, D.C. As I have for many years, I traveled to ACC.14 with my Esperion colleagues to hear firsthand the latest research findings in the prevention, diagnosis and treatment… Read More

Providing an Alternative for LDL-C Lowering

April 9, 2014
Tim Mayleben
President and Chief Executive Officer

Brian Orelli’s recent article in BioWorld Insight, “Avoiding the PCSK9 frenzy with alternative drug targets,” highlights how the focus and excitement around the PCSK9 inhibitors reflects the high level of interest for effective alternatives to statins for low-density lipoprotein cholesterol (LDL-C) lowering. While the PCSK9 inhibitors—injectable biologic therapies—have demonstrated compelling efficacy, Orelli’s piece reminds us… Read More

Why we Like the New AHA/ACC Cholesterol Guidelines

November 17, 2013
Tim Mayleben
President and Chief Executive Officer

On November 12, the American College of Cardiology (ACC) and the American Heart Association (AHA) released new guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease (ASCVD) risk in adults. These guidelines represent an important shift from past cholesterol guidelines and are of particular interest to Esperion because we are working to… Read More

Working to Impact the Lives of Millions of Statin Intolerant Patients

November 11, 2013
Tim Mayleben
President and Chief Executive Officer

I re-joined Roger at Esperion almost a year ago to help people who are at risk for debilitating and life-threatening heart attacks and strokes because they have elevated levels of LDL-C (the bad cholesterol), but who are unable to take a statin because of myalgia (muscle pain). These patients are considered statin intolerant – and… Read More

Posted In: Company News